• IWP-2 in Cancer and Immunology: Beyond Wnt Inhibition

  2026-05-26

  Explore the advanced applications of IWP-2 as a potent Wnt production inhibitor, uniquely positioned at the intersection of cancer research and immunological modulation. This article delivers deep mechanistic insight and practical protocol guidance for innovative scientists.

• Pazopanib Hydrochloride: Optimized Workflows for Cancer Rese

  2026-05-26

  Pazopanib Hydrochloride (GW786034) empowers advanced anti-angiogenic and cytotoxic assays, enabling reproducible modeling of tumor suppression across diverse cancer types. This article delivers actionable protocol enhancements, troubleshooting strategies, and research insights that maximize the translational impact of this multi-target kinase inhibitor.

• Palbociclib (PD0332991): Advancing Tumor Microenvironment Re

  2026-05-25

  This thought-leadership article explores the mechanistic and translational impact of Palbociclib (PD0332991) Isethionate in next-generation cancer models. By integrating recent advances in assembloid technology and cell cycle biology, we provide strategic guidance for translational researchers seeking to optimize experimental design, interpret drug response variability, and bridge bench findings to clinical strategies. The discussion is grounded in recent reference studies and highlights APExBIO’s product reliability in complex model systems.

• Nirmatrelvir (PF-07321332): Applied Workflows for SARS-CoV-2

  2026-05-25

  Nirmatrelvir (PF-07321332) enables targeted SARS-CoV-2 3CL protease inhibition in advanced antiviral therapeutics research. This article details actionable experimental workflows and troubleshooting strategies, translating cutting-edge findings into practical, optimized bench applications.

• Doxycycline in Mechanotransduction: Beyond Antimicrobial Act

  2026-05-24

  Explore Doxycycline, a tetracycline antibiotic, as a precision tool in mechanotransduction and stem cell niche studies. Discover unique insights into its role as a metalloproteinase inhibitor and its advanced applications in cancer and matrix biology research.

• Dehydroepiandrosterone in PCOS & Neuroprotection Workflows

  2026-05-23

  Dehydroepiandrosterone (DHEA) unlocks advanced experimental models for both ovarian and neural research, bridging the gap between apoptosis inhibition and granulosa cell regulation. Discover how APExBIO's DHEA enables reproducible assays, detailed troubleshooting, and translational insights for PCOS and neuroprotection studies.

• Syringin Enhances Sunitinib Efficacy in RCC via EGFR/PI3K/Ak

  2026-05-22

  This study establishes Syringin as a bioactive natural product that inhibits renal cell carcinoma (RCC) cell proliferation, migration, and viability, while promoting apoptosis. By targeting the EGFR/PI3K/Akt pathway, Syringin also enhances RCC cell sensitivity to sunitinib, offering a promising strategy to overcome drug resistance.

• Dual Luciferase Reporter Gene System: Precision in Biolumine

  2026-05-22

  Unlock reproducible, high-throughput gene expression regulation studies using the Dual Luciferase Reporter Gene System. This guide delivers actionable workflows, troubleshooting strategies, and real-world insights, bridging advanced research findings with practical laboratory excellence.

• PDI Inhibition Enhances Panobinostat Efficacy in Multiple My

  2026-05-21

  This study demonstrates that the PDI inhibitor LTI6426 significantly enhances the anti-myeloma efficacy of panobinostat at lower, less toxic doses in preclinical models. The work identifies key ER stress pathway biomarkers and suggests new combination strategies for overcoming proteasome inhibitor resistance in multiple myeloma.

• Salmonella Haem Biosynthesis Suppresses Macrophage Phagocyto

  2026-05-21

  This study uncovers how Salmonella Typhimurium uses a methyltransferase to upregulate haem biosynthesis, directly inhibiting macrophage phagocytosis and enhancing virulence in mice. The findings highlight a post-translational regulatory mechanism in bacterial immune evasion, informing future research on host-pathogen interactions and heme pathway manipulation.

• Optimizing Osteoclastogenesis Studies with BPN-19186

  2026-05-20

  BPN-19186 ((S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea) enables robust and reproducible modulation of redox and signaling pathways in osteoclastogenesis and related biochemical research. This article translates the latest mechanistic insights into actionable protocols, troubleshooting tips, and comparative advantages for scientists investigating bone metabolism and redox imbalance.

• CDK9 Inhibitor (A3294): Technical Protocols and Best Practic

  2026-05-20

  CDK9 inhibitor (A3294) provides selective, non-cytotoxic inhibition of cyclin dependent kinase 9, enabling precise study of transcription elongation and HIV-1 propagation mechanisms. It should not be used for research requiring broad-spectrum CDK inhibition or protocols that demand long-term storage of working solutions. Proper handling and protocol adherence are essential for reproducible results.

• Machine Learning Discovers New Senolytics for Targeting Sene

  2026-05-19

  This article examines a landmark study that leverages machine learning to identify new senolytic compounds from published datasets, dramatically reducing drug screening costs. The findings advance our understanding of selective elimination of senescent cells, an area with major implications for cancer, aging, and degenerative disease research.

• Pexidartinib (PLX3397) for Targeted Tumor Microenvironment M

  2026-05-19

  Pexidartinib (PLX3397) empowers cancer researchers to precisely modulate tumor-associated macrophages, enabling rigorous investigation of anti-tumor immunity and microenvironmental dynamics. This guide delivers actionable experimental workflows, troubleshooting insights, and a synthesis of cutting-edge literature to accelerate translational oncology studies.

• Berberine Inhibits NLRP3 Inflammasome via SIRT6-AMPK in AF M

  2026-05-18

  This study demonstrates that berberine prevents angiotensin II-induced atrial fibrosis and atrial fibrillation (AF) susceptibility by activating the SIRT6-AMPK pathway and inhibiting NLRP3 inflammasome signaling. These mechanistic findings clarify the metabolic-inflammation axis in AF, suggesting new avenues for targeted anti-arrhythmic interventions.

7937 records 11/530 page Previous Next First page 上5页 1112131415 下5页 Last page